Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase 1/2a, Single- and Multiple-dose Escalation Study of KRRO-110
Sponsor: Korro Bio, Inc.
Summary
The purpose of this first-in human (FIH) study is to assess the safety, tolerability, and pharmacokinetics (PK) of single and multiple doses of KRRO-110 in both healthy adult participants and in clinically stable patients with Alpha-1 antitrypsin deficiency (AATD).
Official title: A Phase 1/2a, Single- and Multiple-dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KRRO 110 in Healthy Adult Volunteers and in Adult Participants With Alpha-1 Antitrypsin Deficiency (AATD) (REWRITE)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2025-01-13
Completion Date
2026-12
Last Updated
2025-12-15
Healthy Volunteers
Yes
Conditions
Interventions
KRRO-110
KRRO-110 drug product, IV
Locations (5)
The Prince Charles Hospital
Brisbane, Queensland, Australia
Nucleus Network Pty Ltd
Melbourne, Victoria, Australia
St. Vincent's Hospital Melbourne
Melbourne, Victoria, Australia
New Zealand Clinical Research
Auckland, New Zealand
New Zealand Clinical Research
Christchurch, New Zealand